MANAGE-HCM: Mavacamten Effectiveness in Obstructive Hypertrophic Cardiomyopathy, Japan
Summary
NIH ClinicalTrials.gov registered observational study NCT07541833 titled MANAGE-HCM on April 21, 2026. The study will assess real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy receiving cibenzoline in Japan. The study is categorized as observational with mavacamten as the sole intervention.
“The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan”
What changed
NIH ClinicalTrials.gov registered a new observational study (NCT07541833, MANAGE-HCM) on April 21, 2026. The study will evaluate the real-world effectiveness and safety of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are receiving cibenzoline in Japan.
Affected parties include pharmaceutical companies, healthcare providers, and patients in Japan involved in hypertrophic cardiomyopathy treatment. The registry entry documents a planned observational study and does not impose any compliance obligations or regulatory requirements.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
Observational NCT07541833 Kind: OBSERVATIONAL Apr 21, 2026
Abstract
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan
Conditions: Cardiomyopathy
Interventions: Mavacamten
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.